Similar articles

• [More attention should be paid to the understanding of gastroenteropancreatic neuroendocrine tumors].

  Xu JM. Xu JM. Zhonghua Zhong Liu Za Zhi. 2012 Feb;34(2):158-60. doi: 10.3760/cma.j.issn.0253-3766.2012.02.018. Zhonghua Zhong Liu Za Zhi. 2012. PMID: 22780939 Chinese. No abstract available.
• Steve Jobs's cancer. Pancreatic neuroendocrine tumors are becoming more common (the bad news) and also more treatable (the good news).

  [No authors listed] [No authors listed] Harv Health Lett. 2012 Jan;37(3):1-3. Harv Health Lett. 2012. PMID: 22400158 No abstract available.
• Pancreatic neuroendocrine and carcinoid tumors: what's new, what's old, and what's different?

  Reidy-Lagunes D, Thornton R. Reidy-Lagunes D, et al. Curr Oncol Rep. 2012 Jun;14(3):249-56. doi: 10.1007/s11912-012-0232-1. Curr Oncol Rep. 2012. PMID: 22434313 Review.
• New directions in the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): shifting from symptom management to targeting tumors.

  Weber M. Weber M. Clin Adv Hematol Oncol. 2014 Dec;12(12 Suppl 19):12-7. Clin Adv Hematol Oncol. 2014. PMID: 25768104 Review. No abstract available.
• New target therapies for patients with neuroendocrine tumors of the pancreas.

  Baltogiannis G, Katsios C, Roukos DH. Baltogiannis G, et al. Expert Rev Gastroenterol Hepatol. 2011 Oct;5(5):563-6. doi: 10.1586/egh.11.55. Expert Rev Gastroenterol Hepatol. 2011. PMID: 21910571 No abstract available.